Nevro Corp., a medical device company focused on improving pain relief
among patients suffering from debilitating chronic pain, announced today
the issuance of two key patents related to the company's Senza™
High-Frequency Spinal Cord Stimulation System.
U.S. Patent No. 8,170,675 includes multiple claims directed to methods
for delivering pulsed electrical signals to the epidural space of the
spinal cord at frequencies between about 1.5 kHz and about 50 kHz to
relieve a patient's chronic leg and/or back pain without creating
paresthesia. Paresthesia is typically a tingling, buzzing sensation
associated with conventional low-frequency spinal cord stimulation
systems that patients often find unpleasant.
An additional patent, No. 8,209,021, includes medical apparatus claims
that correspond to many of the method claims of U.S. Patent No.
8,170,675.
"We believe these patents validate the distinct nature of our
technology," said Nevro's President and Chief Executive Officer Michael
DeMane. "Their issuance represents an important milestone in the
development of the technology and underscores Nevro's position at the
forefront of innovation in the field of spinal cord stimulation."
Further patent applications covering many other aspects of Nevro's
proprietary technology are pending in the U.S. and abroad.
Active feedback improves pharmacist participation in heart failure treatment